Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US Election 2016

Set Alert for US Election 2016

Trump’s Rx For The Drug Industry: Take Two And Have No Idea What Will Happen In The Morning

To call the incoming US president unpredictable would be an understatement, but that doesn’t mean that industry shouldn’t know what to expect.

US Election 2016 Policy & Regulation BioPharmaceutical

Latest From US Election 2016 & BioPharmaceutical

Rhetoric Meets Reality: A Timeline Of Trump's First 100 Days

President Trump is empty-handed on health care victories so far, as initial health reform repeal efforts collapsed and the shock value of drug pricing tweets wore off. But some actions may evolve into biopharma impact further down the road.

Policy FDA

Podcast: Trump's 100 Day Test

Trump-watchers, check out our new podcast covering Trump's first months in office and the full GOP policy agenda. (Free with registration.)

BioPharmaceutical US Election 2016

Trump’s Next 1,000 Days: Advice For The Pharma C-suite

Although signs suggest the Trump Administration is moving back to the establishment center, biopharma’s knowledge elites remain in the populists’ crosshairs. It’s vital to change the narrative on medicines and markets. In this brief opinion piece In Vivo provides seven ways for the C-suite to do just that.

BioPharmaceutical Leadership

Trump Has Won On Drug Prices – According To Breitbart

The pharmaceutical industry is always struggling to get good press when it comes to drug prices. But a recent headline in Breitbart News is one to savor – as long as the President believes it.

Pricing Debate Policy

PhRMA And Trump: 'Go Boldly,' Or Tread Carefully?

Brand name industry’s image campaign promises to 'Go Boldly' – but there has been nothing bold about its public response to the Trump Administration’s efforts to repeal the Affordable Care Act, the President’s strong words on drug pricing, or even proposed cuts to NIH funding and FDA. Treading carefully makes a lot of sense – but is there a line that PhRMA won’t let the Administration cross?

Pricing Debate Legislation

To Get Pricing Right, Pharma Must Understand Payer Behavior, Trump Or No Trump

When it comes to drug pricing, one size certainly doesn’t fit all. Biopharma firms need to devise and design appropriate pricing and commercial strategies for payers, a group of customers that don’t all care about the same things and, in some cases, whose needs may be diametrically opposed.

Reimbursement Pricing Debate

US Healthcare Bill's Failure Could Have Unpleasant Ripple Effects For Pharma

Having sat on the sidelines during the unsuccessful effort to repeal and replace Obamacare, the pharma industry may find the rest of its legislative agenda, from taxes to even user fee reauthorization, could become more difficult.

US Election 2016 Legislation

Pfizer On Obamacare Rewind: No Short-Term Impact On Industry

Pfizer CEO Ian Read explains why industry has stayed on the sidelines during the current health reform debate and defends drug pricing practices during a speech to the National Press Club.

Policy Pricing Debate

Trump's Greatest Hits: Drug Price Controls As Part Of The Repertoire

President's pledge to merge drug pricing control with a revamp of the Affordable Care Act wins applause at Kentucky rally, where the president reeled through a number of his populist issues, even as the idea makes scant legislative progress.

Policy Pricing Debate
UsernamePublicRestriction

Register